All Open Clinical Trials
Below is a list of all open NCI Center for Cancer Research (CCR) clinical trials, including studies that are currently recruiting patients (i.e. Open - Recruiting) as well as trials that will be recruiting soon (i.e., Open - Not yet Recruiting). Most recently opened trials are listed first.
All CCR clinical trials take place at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland.
Clinical trials at the NIH Clinical Center are open to patients with cancer, HIV, or immunodeficiency disorders, regardless of where they live in the United States.
-
Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Peripheral T cell Lymphoma
Open - Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-19-C-0085Investigator Jennifer A. Kanakry, M.D. -
Natural History Study of Children and Adults with Chordoma
Open - Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-19-C-0082Investigator Brigitte C. Widemann, M.D. -
A Phase 1/2, Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination with Pembrolizumab (KEYTRUDA) with Relapsed or Refractory Solid Tumors
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0077Investigator Christina M. Annunziata, M.D., Ph.D. -
A Phase 1/2, Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination with Pembrolizumab (KEYTRUDA) with Relapsed or Refractory Solid Tumors
Open - Not yet RecruitingNCI Protocol ID NCI-17-C-0077Investigator Christina M. Annunziata, M.D., Ph.D. -
A Phase II Pilot Study of Avelumab in Combination with Hypofractionated Radiotherapy in Patients with Relapsed Refractory Multiple Myeloma
Open - Not yet Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-19-C-0078Investigator Dickran G. Kazandjian, M.D. -
A Phase 1 Study of Interleukin-15 in Combination with Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
Open - Not yet Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-19-C-0076Investigator Milos Miljković, M.D., M.Sc. -
A Phase I Study of Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Local-Regionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Open - RecruitingNCI Protocol ID NCI-19-C-0041Investigator Vassiliki Saloura, M.D. Ph. D. -
A Phase II Study of Neoadjuvant Androgen Deprivation Therapy Combined with Enzalutamide and Abiraterone Using Multiparametric MRI and 18F-DCFPyL-PET/CT in Newly Diagnosed Prostate Cancer
Open - RecruitingNCI Protocol ID NCI-19-C-0062Investigator William L. Dahut, M.D. -
A Phase 2 Trial of The MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0061Investigator Brigitte C. Widemann, M.D. -
Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.
Open - RecruitingNCI Protocol ID NCI-19-C-0046Investigator James N. Kochenderfer, M.D. -
Long term follow-up of mesothelioma patients and their family members with germline mutations in BAP1 and other genes
Open - RecruitingNCI Protocol ID NCI-19-C-0049Investigator Raffit Hassan, M.D. -
A Phase I study of Moxetumomab pasudotox (Lumoxiti™) and Rituximab (Rituxan®) for Relapsed Hairy Cell Leukemia
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0042Investigator Robert J. Kreitman, M.D. -
Natural History Study of Men at High Genetic Risk for Prostate Cancer
Open - RecruitingNCI Protocol ID NCI-19-C-0040Investigator William L. Dahut, M.D. -
Perioperative MVT-5873, a fully human monoclonal antibody against a CA 19-9 epitope, for operable CA 19-9 producing pancreatic cancers, cholangiocarcinomas, and metastatic colorectal cancers
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0039Investigator Jonathan M. Hernandez, M.D. -
An open-label, first-in-human, multi-center study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of a thorium-227 labeled antibody-chelator conjugate, BAY 2287411 Injection, in patients with solid tumors known to express
Open - RecruitingNCI Protocol ID NCI-19-C-0038Investigator Raffit Hassan, M.D. -
Phase II Study of Nivolumab (anti-PD1), Tadalafil and Oral Vancomycin in Patients with Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer from Colorectal or Pancreatic Cancers
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0033Investigator Tim F. Greten, M.D. -
A Phase 2 Study of Response-Adapted Therapy with Copanlisib and Rituximab in Untreated Follicular Lymphoma #xD;
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0030Investigator Mark Roschewski, M.D. -
Tissue Acquisition and Genomics Analysis of Breast and Other Gynecologic Malignancies
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0025Investigator Christina M. Annunziata, M.D., Ph.D. -
A Phase II Study of Olaparib in Patients with Metastatic/Advanced Urothelial Carcinoma with DNA-Repair Defects
Open - RecruitingNCI Protocol ID NCI-19-C-0023Investigator Andrea B. Apolo, M.D. -
Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
Open - RecruitingNCI Protocol ID NCI-19-C-0024Investigator Milos Miljković, M.D., M.Sc.